Show simple item record

dc.contributor.authorKiguchi, Norikazu
dc.contributor.authorDing, Huiping
dc.contributor.authorCami-Kobeci, Gerta
dc.contributor.authorSukhtankar, Devki D.
dc.contributor.authorCzoty, Paul W.
dc.contributor.authorDeLoid, Heather B.
dc.contributor.authorHsu, Fang-Chi
dc.contributor.authorToll, Lawrence
dc.contributor.authorHusbands, Stephen M.
dc.contributor.authorKo, Mei-Chuan
dc.identifier.citationKiguchi N, Ding H, Cami-Kobeci G, Sukhtankar DD, Czoty PW, DeLoid HB, Hsu FC, Toll L, Husbands SM, Ko MC (2019) 'BU10038 as a safe opioid analgesic with fewer side-effects after systemic and intrathecal administration in primates', British Journal of Anaesthesia, 122 (6), pp.e146-e156.en_US
dc.description.abstractBackground: The marked increase in mis-use of prescription opioids has greatly affected our society. One potential solution is to develop improved analgesics which have agonist action at both mu opioid peptide (MOP) and nociceptin/orphanin FQ peptide (NOP) receptors. BU10038 is a recently identified bifunctional MOP/NOP partial agonist. The aim of this study was to determine the functional profile of systemic or spinal delivery of BU10038 in primates after acute and chronic administration. Methods: A series of behavioural and physiological assays have been established specifically to reflect the therapeutic (analgesia) and side-effects (abuse potential, respiratory depression, itch, physical dependence, and tolerance) of opioid analgesics in rhesus monkeys. Results: After systemic administration, BU10038 (0.001–0.01 mg kg−1) dose-dependently produced long-lasting antinociceptive and antihypersensitive effects. Unlike the MOP agonist oxycodone, BU10038 lacked reinforcing effects (i.e. little or no abuse liability), and BU10038 did not compromise the physiological functions of primates including respiration, cardiovascular activities, and body temperature at antinociceptive doses and a 10–30-fold higher dose (0.01–0.1 mg kg−1). After intrathecal administration, BU10038 (3 μg) exerted morphine-comparable antinociception and antihypersensitivity without itch scratching responses. Unlike morphine, BU10038 did not cause the development of physical dependence and tolerance after repeated and chronic administration. Conclusions: These in vivo findings demonstrate the translational potential of bifunctional MOP/NOP receptor agonists such as BU10038 as a safe, non-addictive analgesic with fewer side-effects in primates. This study strongly supports that bifunctional MOP/NOP agonists may provide improved analgesics and an alternative solution for the ongoing prescription opioid crisis.en_US
dc.publisherElsevier Ltden_US
dc.rightsGreen - can archive pre-print and post-print or publisher's version/PDF
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.subjectrhesus macaqueen_US
dc.subjectopiate addictionen_US
dc.subjectopioid-related disordersen_US
dc.subjectSubject Categories::B200 Pharmacology, Toxicology and Pharmacyen_US
dc.titleBU10038 as a safe opioid analgesic with fewer side-effects after systemic and intrathecal administration in primatesen_US
dc.contributor.departmentWake Forest Universityen_US
dc.contributor.departmentWakayama Medical Universityen_US
dc.contributor.departmentUniversity of Bathen_US
dc.contributor.departmentWake Forest Baptist Medical Centeren_US
dc.contributor.departmentFlorida Atlantic Universityen_US
dc.contributor.departmentW.G. Hefner Veterans Affairs Medical Centeren_US
dc.identifier.journalBritish Journal of Anaesthesiaen_US
dc.description.notefull text from

Files in this item

Publisher version

This item appears in the following Collection(s)

Show simple item record

Green - can archive pre-print and post-print or publisher's version/PDF
Except where otherwise noted, this item's license is described as Green - can archive pre-print and post-print or publisher's version/PDF